WINNIPEG, MANITOBA--(Marketwire - May 08, 2008) - Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, has closed its previously announced private placement (the “Offering”) with aggregate gross proceeds to the Company of $625,064.70 from the sale of 4,167,098 units (the “Units”) at a price of $0.15 per Unit. Each Unit is comprised of one common share of the Company (a “Share”) and one-half of one Share purchase warrant (a “Warrant”). Each whole Warrant entitles the holder thereof to purchase one Share at a price of $0.25 for a period of twelve months from the date of issuance of the Warrant. The net proceeds of the Offering shall be used for research and development and working capital purposes. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws and the policies of the TSX Venture Exchange.
